incb7839
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00820560)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- incb007839
- incb7839
- incb7839
- incb7839
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04295759 | Phase 1 | Apr 11, 2020 | Pediatric Brain Tumor Consortium, Stanford University |
| NCT02141451 | Phase 1/Phase 2 (Phase 2) | May 1, 2014 | University of Minnesota |
| NCT01254136 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Incyte, SCRI Development Innovations |
| NCT00864175 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | Incyte |
| NCT00820560 | Phase 1 | Jan 1, 2005 | Incyte |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 3 | 3 | 2 | 2005 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2020 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2010 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2014 |
5 organizations
Page 1 / 1